fluid_neutral

CAN LIVING ORGANISMS SUCH AS PLANTS AND ANIMALS BE INVENTED? AND SHOULD PRIVATE COMPANIES BE ALLOWED TO CLAIM SUCH SUPPOSED INVENTIONS FOR THEMSELVES? NO!

As a result, we concluded that the formation of a part of Omicron isolates BA.1, BA.1.1, and BA.2 was not the product of genome evolution, as is commonly observed in nature, such as the accumulation of mutations and homologous recombinations. Furthermore, the study of 35 recombinant isolates of Omicron variants BA.1 and BA.2 confirmed that Omicron variants were already present in 2020. The analysis showed that Omicron variants were formed by an entirely new mechanism that cannot be explained by previous biology, and knowing how the SARS-CoV-2 variants were formed prompts a reconsideration of the SARS-CoV-2 pandemic

As a result, we concluded that the formation of a part of Omicron isolates BA.1, BA.1.1, and BA.2 was not the product of genome evolution, as is commonly observed in nature, such as the accumulation of mutations and homologous recombinations. Furthermore, the study of 35 recombinant isolates of Omicron variants BA.1 and BA.2 confirmed that Omicron variants were already present in 2020. The analysis showed that Omicron variants were formed by an entirely new mechanism that cannot be explained by previous biology, and knowing how the SARS-CoV-2 variants were formed prompts a reconsideration of the SARS-CoV-2 pandemic

Results: ... we found preliminary evidence of a dose response relationship of the amount of DNA per dose and the frequency of serious adverse events (SAEs). This relationship was different for the Pfizer and Moderna products. Size distribution analysis found mean and maximum DNA fragment lengths of 214 base pairs (bp) and 3.5 kb, respectively. The plasmid DNA is likely inside the LNPs and is protected from nucleases. Conclusion: These data demonstrate the presence of billions to hundreds of billions of DNA molecules per dose in these vaccines. Using fluorometry, all vaccines exceed the guidelines for residual DNA set by FDA and WHO of 10 ng/dose by 188 – 509-fold...

https://www.regulations.gov/document/EPA-HQ-OPP-2019-0274-0470

On the basis of the information furnished by you, the subject Experimental Use Permit (EUP) under section 5 of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) is hereby amended and extended for the release of OX5034 Aedes aegypti mosquitoes containing Tetracycline Trans-Activator Variant (tTAV-OX5034) protein and the genetic material (from vector pOX5034) necessary to produce the protein in vivo. The EUP, which is authorized only in the states of Florida and California, will evaluate efficacy of release of adult and eggs of OX5034 Aedes aegypti mosquitoes against wild Aedes aegypti mosquitoes within Monroe County, Florida and Stanislaus, Fresno, Tulare, and San Bernardino counties, California. Shipment and/or use under this permit are subject to the provisions of 40 CFR Part 172.

These conditions take effect today and require certain online streaming services to provide the CRTC with information related to their content and subscribership.